UnitedHealth Buy Rating Affirmed Amidst Medicare Advantage Growth and Positive Sector Outlook
UBS Raises Price Target on Eli Lilly to $1,100 From $910, Maintains Buy Rating
Stifel Nicolaus Remains a Hold on Johnson & Johnson (JNJ)
AbbVie Analyst Ratings
Merck & Co Analyst Ratings
Amgen Analyst Ratings
Berenberg Maintains Buy on Eli Lilly and Co, Raises Price Target to $1000
Morgan Stanley Adjusts Price Target on Amgen to $303 From $310
Morgan Stanley Adjusts Price Target on AbbVie to $196 From $191
Morgan Stanley Adjusts Price Target on Merck to $134 From $132
Berenberg Adjusts Price Target on Eli Lilly & Co. to $1,000 From $850, Maintains Buy Rating
Analysts Offer Insights on Healthcare Companies: AbbVie (ABBV), Roche Holding AG (OtherRHHVF) and UnitedHealth (UNH)
Buy Rating Affirmed for Abbott Laboratories Amidst Strong Growth and Manageable Risks
Eli Lilly and Co Analyst Ratings
Goldman Sachs Adjusts Price Target on Abbott Laboratories to $118 From $121
Redburn Atlantic Adjusts Price Target on AbbVie to $203 From $207
Analysts' Opinions Are Mixed on These Healthcare Stocks: Neurocrine (NBIX) and AbbVie (ABBV)
AbbVie (ABBV) Gets a Buy From Barclays
Cantor Fitzgerald Keeps Their Buy Rating on UnitedHealth (UNH)
Cantor Fitzgerald Reiterates Overweight on UnitedHealth Group, Maintains $591 Price Target